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In 2005, a 62-year-old man was diagnosed with stage IIIBnon-small cell lung cancer and treated with sequential
chemoradiotherapy. Approximately 2 years later, he was
treated with the endothelial growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) gefitinib. Eight days after
starting getitinib therapy, he experienced grade 3 skin toxicity
on the chest and shoulders but not in the previous radiother-
apy field (Figure 1).1,2 Despite the severity of the skin
toxicity, the patient did not obtain any benefit from this
treatment.
In reviewing the existing literature on this topic, we
observed that the sequential approach of radiotherapy fol-
lowed by EGFR-TKI does not seem to have a synergic or
additive effect, as observed with the concomitant approach.
Conversely, this effect seems to be detrimental, perhaps by
inducing a decrease in expression and activity of EGFR. This
effect seems to be milder if EGFR-TKI is administered
immediately after radiotherapy (within 3 weeks) and much
stronger when administered after a longer time from radio-
therapy.3,4 These data suggest that the decrease of EGFR
expression after radiotherapy may have a dramatic role in
explaining the negative preliminary results of SWOG 0023,
which is the only clinical study available so far.5 This obser-
vation raises the question of whether skin toxicity sparing can
be considered a surrogate of lack of tumor response to
EGFR-TKIs.
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FIGURE 1. Skin toxicity on the chest and shoulders but not
in the previous radiotherapy field (8 days after gefitinib
treatment).
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